AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK
AstraZeneca’s COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New Year.
AstraZeneca to acquire Alexion, accelerating the company's strategic and financial development
AstraZeneca and Alexion Pharmaceuticals, Inc. have entered into a definitive agreement for AstraZeneca to acquire Alexion.
AstraZeneca's COVID-19 vaccine shows promise among older people in trials
Strong immune responses were demonstrated across all age groups and boosted after a second dose.
Phase I clinical trial initiated for monoclonal antibody combination for prevention and treatment of COVID-19
The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19, reports AstraZeneca.
AstraZeneca concludes agreement with the European Commission for supply of COVID-19 vaccine
AstraZeneca has concluded an agreement with the European Commission (EC) to supply up to 400 million doses of the AZD1222 COVID-19 vaccine.
AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise new antibody drug conjugate
Potential new medicine DS-1062 could redefine treatment standards in lung, breast and multiple other cancers.
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.
AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford’s potential new vaccine
AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford’s potential vaccine widely accessible around the world in an equitable manner.
AstraZeneca publishes COVID-19 Employee and Leader Toolkits
AstraZeneca has developed valuable toolkits to help both leaders and employees effectively navigate through the COVID-19 crisis. Both toolkits are now available for download.
AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine
AstraZeneca and the University of Oxford today announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2.
AstraZeneca joins UK Government’s ACCORD trial platform
AstraZeneca is joining forces with public research bodies and academic institutions as part of a UK government-led initiative to speed up the development of medicines to treat patients hospitalised with COVID-19.
AstraZeneca reports robust first quarter results
AstraZeneca delivered a quarter of strong revenue and profit growth, reflecting the immense efforts of supply-chain, commercial and other colleagues around the world to get vital medicines to patients. As part of the fight, the Company has rapidly responded to the pandemic, firstly in China and then globally.
AstraZeneca initiates clinical trial with Calquence against COVID-19
AstraZeneca will initiate a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib), a blood cancer drug, in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in severely ill patients.
AstraZeneca is researching antibodies to target COVID-19
AstraZeneca is joining forces with government and academia with the aim of discovering novel coronavirus-neutralising antibodies.
AstraZeneca donates 9 million face masks to support healthcare workers around the world in the fight against COVID-19
AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZeneca has partnered with the World Economic Forum’s COVID Action Platform, created with the support of the World Health Organisation, to identify countries in greatest need.
St George Street Capital agrees deal with AstraZeneca to drive science to patients in need
St George Street Capital (SGSC), a UK registered charity, has signed a licence agreement with AstraZeneca to develop two compounds in the clinic: one for idiopathic male infertility, and the other for renal transplant rejection. The agreement enables additional compounds to be added in the future.
World leading antibody scientist Dr Jane Osbourn awarded OBE in Queen’s Honours
Dr Jane Osbourn, Vice-President of Research and Development at AstraZeneca, has been made an Officer of the Order of the British Empire (OBE) in the Queen’s birthday honours list.
AstraZeneca announces StartUP Science Competition 2019
AstraZeneca is hosting its second StartUP Science Competition for life science entrepreneurs in the Cambridge area.
Lynparza approved in EU for the treatment of breast cancer
AstraZeneca and MSD Inc. have announced the European Commission has approved Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer.
AstraZeneca medicine approved in Europe for type-1 diabetes
AstraZeneca's Forxiga is the first oral medicine approved in Europe as an adjunct to insulin for adults with type-1 diabetes and the first AstraZeneca medicine ever approved for type-1 diabetes.
AstraZeneca presents advances in treatment options for ovarian and lung cancer patients
AstraZeneca and MedImmune, its global biologics research and development arm, will present 54 abstracts, including eight oral presentations and three late breakers, to the ESMO 2018 Congress (European Society for Medical Oncology) in Munich, Germany, 19-23 October.
Attention life science entrepreneurs! Enter AstraZeneca's 'Start-Up Science' competition
Are you an early-stage Cambridge start-up focused on life sciences/healthcare? Time is running out to enter AstraZeneca's first ever Start-Up Science competition for life science entrepreneurs in the Cambridge area.
Cambridge life sciences cluster set to deliver additional £1billion to the UK economy by 2032
The Cambridge life sciences cluster has the potential to contribute an additional £1bn to the UK economy by 2032, according to independent research commissioned by AstraZeneca.
AstraZeneca and Lucy Cavendish College establish mentoring collaboration
AstraZeneca and Lucy Cavendish College, University of Cambridge, today announced that they have established a strategic collaboration to support their common goals of advancing women in science and business leadership, building on their existing relationship since the Company relocated its global HQ and R&D centre to Cambridge in 2016.
AstraZeneca aims to advance clinical practice in CV risk management with new data at ACC 2018
At the American College of Cardiology (ACC) 67th Annual Scientific Session & Expo 2018 in Orlando, Florida, this weekend, AstraZeneca will deliver industry-leading science and insights that augment the body of evidence on clinical approaches to tackling cardiovascular diseases.